Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
Founder, CEO and managing director of Vailshire Capital Management, LLC, in Colorado Springs. Managing director of Vailshire Partners, LP: a multi-strategy "two-pronged" hedge fund seeking present value, future growth, and current income through an active safe options strategy. The fund frequently sells covered calls and naked puts to earn generous income and profit from market volatility. As a physician, a strong emphasis is placed on health care, pharmaceutical and biotech equities. Transitioned in 2015 from full- to part-time medicine as a Diagnostic and Interventional Radiologist in Colorado Springs, CO. Currently a full-time investment professional, managing the hedge fund and 50+ separately managed accounts via Vailshire Capital Management. For inquiries, please use my personal email: email@example.com
Hello, my name is Dieter and I run a Belgian-based consultancy and coaching firm specialized in giving training and guidance to investors during their journey on the financial markets. We are best at writing crystal clear analysis and providing clear and understandable investment advise for our customers.
We are specialized in European markets and European shares.
Contact us via: firstname.lastname@example.org
Jonathan co-founded Booth-Laird Enterprises, LLC in 2007 and serves as the company’s chief executive officer. He is primarily responsible for structuring and overseeing the company’s vision of wealth creation via value-decision making, setting an appropriate culture, and overseeing the company’s investments.
Jonathan is a Chartered Financial Analyst and a Certified Public Accountant. He was awarded the 2006 Elijah Watt Sells award for scoring one of the 10 highest scores in the nation on the 2006 CPA exam. He also passed all three levels of the CFA exam on his first attempt. In addition, he was awarded the 2008 “Top 40 Under Forty” award from the Greater Baton Rouge Business Report, which is given annually to the forty men and women under the age of forty who have earned the most personal and professional achievements or made the most significant impact in the Greater Baton Rouge area.
He worked for three years as an auditor with Ernst & Young, LLP and KPMG, LLP, two of the four largest accounting firms in the world. At both firms, he was rated “exceptional performer” every year and was entrusted with responsibilities above his level within months of starting with each firm. He audited both public and private companies in a variety of industries, including acting as the lead audit senior on a Fortune 500 company. He was regularly assigned the most complex accounting issues and the most challenging audit areas. As a result of his experience, he has developed an astute understanding of risk management, team management, optimal business processes, effective corporate governance practices, and various industries and business models.
While at KPMG, he served as the only South Louisiana member on the KPMG Point-of-View group, an internal group of highly rated employees across the United States focused on strategic initiatives and determining best practices.
Subsequent to KPMG, he worked for a year in Governor Bobby Jindal’s administration as the Assistant Director of State Economic Competitiveness, a subgroup of the Department of Economic Development charged with helping to shape the State’s economic policy in addition to various other tasks. Among a number of other significant projects, he helped craft the department-wide business plan for Fiscal Year 2009-2010, which further developed his strategic planning capabilities. He also met with representatives of the business community to help resolve issues or to hear proposals, which gave him further insight into various industries and business models.
Jonathan earned a bachelor’s of science in accounting from Louisiana State University, graduating summa cum laude, and earned a master of science in accounting from Louisiana State University, graduating top of his class with a perfect 4.0 GPA.
I'm retired from a near 40 year career in the publishing industry working with an international publishing company. My investing experience is over a span of 40 years. Luckily with more winners than losers! My hobbies are world travel, reading good books(non-fiction)--and researching stocks that I have an interest. In my retirement, I volunteer my time working in assisting several lawyers with their Child Protective Service cases.(Drugs are destroying our Society and family structure) I also serve as a reviewer for a national literary prize given each year.
I am a medical professional that enjoys investing in biotech stocks. I take long positions and may dabble in options. I have a particular interest in biotechs with an ophthalmic (eye) focus as that is where I have developed the greatest expertise over my career and research. I hope over time to share some of my professional insights with those of the Seeking Alpha community in order to help them make more informed investing decisions. I expect to learn a lot from others as well.
I am long the following biotechs at this time: GILD, OPHT, CRMD, ACAD, RLYP, HALO, TGTX, APHB, ZIOP.
I am advising everyone to avoid: OHRP
Bay Area Biotech is a group of self-organized life science graduate/medical/business students and postdoctoral scholars who are interested in utilizing our scientific training to evaluate biotechnologies and identify investment opportunities. Opinions published here are those of the authors.
I have been investing in small and mid-cap biotechs for 4 years. My industry experience as a biostatistician on several phase 1-3 trials helps me with my investment decisions. I usually look for opportunities in oncology, ophthalmology, and neuroscience space.
Andrew McDonald is a healthcare investment professional with expertise in identifying transformative medicines as well as in forecasting clinical trial, regulatory, and sales outcomes. Prior to co-founding LifeSci Advisors, Andrew most recently served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Co-head of Healthcare Research and Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer from 2000-2001. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
A researcher into gene silencing as a technology for improving the lives of those suffering from incurable diseases. Benitec Biopharma is my primary investment in this technology as ddRNAi offers one-time treatments for a broad range of these diseases.
Tony Schwartz, PhD is involved in several start-up biotechnology companies (Currently Founder/President of the Athencion Corp). In addition he works with the NIH/NCI to develop novel immunotherapies for cancer. He was formerly the president of the Interthyr Corp. which received FDA and CE mark approval of a medical device for thyroid disease and additionally had several small molecule drugs in preclinical development to the IND phase. He is the co-inventor and patent holder on several drugs that modulate the Toll-like Receptor signaling pathways and has published several publications in high impact factor peer-reviewed journals and books. His research and commercialization interests include cancer, autoimmunity and various endocrine diseases specifically focusing on CD47 and TLRs. Tony obtained his PhD in Biomedical Engineering as well as MBA curriculum at Colorado State University. His research focused the use of mesenchymal stem cells for bone regeneration after radiation therapy of osteosarcoma and Ewing’s sarcoma. His work also developed new radiation therapy protocols to increase tumor kill while protecting normal tissues. He also spearheaded an ongoing clinical trial for the treatment of toxic shock with one of the drugs he developed. In addition, he teaches/develops MBA courses at Johns Hopkins focusing on the finance industry in biotechnology. Tony obtained his BS and MS degrees in Electrical Engineering and Computer Science as well as Biomedical Engineering from The Ohio University.
I am currently an individual investor with focus on event-driven trading and long-short opportunities. I graduated Emory University in 2009 and am also a finance Phd dropout from UCLA Anderson. I could be reached at email@example.com
I used to run a limited partnership, boutique hedge fund in the 90s. Retired in 2000 and moved from New York City to Toronto, Canada, got married, raised a family and basically settled down. After a few years in Toronto, my wife got tired of the city’s 8 months of cold weather and insisted that we move to a city where there are 8 months of warm and balmy weather. So we settled on San Diego, CA and moved here in 2005 and now call this lovely city with the most perfect weather, home. After moving to Sun Diego, I decided to come out of retirement and start an Internet company that helps non-profits, especially school PTAs, raise money. After a somewhat long development period, my start-up, called donornation.org, went live this month (December 2012)! The response so far has been quite encouraging and I intend to take the company from its current, local San Diego focus, to nationwide, hopefully in the next 2 years. Feel free to check it out and let me know what you think…any feedback and suggestions to help improve the site is always welcome. Being that my day job is running a tech start-up, I don’t have the time to be an active trader…However, being an avid market watcher and investor, I started this blog to maintain a public record of my views on the economy, the markets and my stock picks. My space here has given me the opportunity to share my analysis, good, bad and the ugly, with everyone. It has also allowed me to keep a running scorecard on how effective my investment ideas have been. About a year ago, just after my Options2Wealth blog's public portfolio recorded 10,000%+ return in less than 6 months, I received an offer to write a book based on my blog's accomplishment by one of the most respected literary agents in the United States. This was a totally unintended and unexpected result of my original motivation which was to simply help demystify derivatives (options) and show how just about anyone, armed with the ability to read stock charts, can take advantage of the most powerful wealth building tool legally available to us all. Based on the fact that some of my readers were able to mimic my moves and achieve returns of as much as 4,000%+ tells me that my blog has succeeded in its raison d'être. Finally, I shall be remiss if I did not acknowledge the many public and private comments / messages that I have received, and continue to receive, from my readers here. I want to take this opportunity to let you know that I'm extremely grateful, and humbled, to all those who have taken the time to share your comments, kind thoughts and warm wishes with me...Should you not receive a reply, please do not take my lack of responsiveness as a sign of hubris...Due to my various interests and activities and the fact that I spend a considerable amount of time traveling, my free time is extremely limited and if I have not responded to your message, please accept my sincere apologies... Best of Luck to All! karim pirani
Medical doctor and independant investor. My investment strategy is to utilize my medical education, combined with market technical and fundamental analysis, to find undervalued biopharmaceutical investments which have a high likelihood of increasing in value over a specified time period. I look for companies whose stocks have recently dropped due to technical factors, misunderstood data or undervalued market opportunity among other factors.
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science.
Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity.
Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering.
With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.
We look for potentially undervalued stocks in biotech, technology, and commodities sectors.
The long and short of it.
We perform research, and give investment opinions and ideas to buy-side firms from time to time.
We are not advisors.
I'm a German event-driven investor with a combination of both Merger Arbitrage and Distressed Securities. Mainly experienced in Corporate & Investment Banking for a French bank and asset management for a german investment company. Graduated in Finance with a main focus on event-driven studies and financial restructuring.
I am a Ph.D. Geneticist with more than 20 years post-graduate working experience in a variety of laboratory settings. I have experience and direct expertise with Genetics, Population Genetics, Biologically-based Chemistry, Molecular Biology and Methods Development and Validation.
My biggest interests for speculative investments are in biotech and nanotech arenas - especially in developmental stage and pre-clinical stage biomedical companies.
Holmes Osborne has been principal of Osborne Global Investments since 2004. Holmes holds the Chartered Financial Analyst designation and a degree in finance from Syracuse University. He has been featured three times in the Wall Street Journal and once in Fortune Magazine and Investors' Business Daily. Holmes has written financial columns for Seeking Alpha, the Motley Fool, and theStreet.com. Client assets are held at Charles Schwab. He lives with his wife Jennifer and daughters Adelaide and Emily.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
I have worked in corporate finance for three Fortune 500 companies including those in the Oil and Gas, Building Materials, and Retail sectors. Most recently I moved to California to work for a multi-billion tech company in Silicon Valley. I will never write articles about the company I am currently working for due to the sensitivity of the information I deal with everyday.
I am an independent equities trader focused on uncovering unknown gems in the market. I graduated from UCLA in 2012 with a degree in Biology and am mostly focused on trading the Biotechnology sector. I look for stocks that have upcoming catalyst events which are under the radar and undervalued by the market. I am the Director and Co-founder of BiotechBreakouts.com, where I look to capture the biggest percentage gains, while minimizing risk.
Ranked #18 overall blogger by TipRanks for 2014.
University of Virginia, class of 2011 B.A. English
I am a young investor focused primarily on dividend growth stocks. Seeking Alpha, and more specifically, the dividend and income community that exists here, has played a significant role in my development as a portfolio manager. I am not a professional, though I do manage my family's finances. I enjoy the process; the research, the decision making, the strategic planning...and not paying a financial adviser to do the work for me. I've built what I believe to be a conservative, diverse, and balanced dividend growth portfolio currently consisting of 48 positions. Thus far, I've been able to meet by goals from income, income growth, and capital appreciation standpoints. I use a wide variety of metrics, both fundamental and technical, when establishing fair value when doing my due diligence on an individual company. All of my methods are discussed in my work here. I hope this work inspires debate, conversation, and education - this is why I write for Seeking Alpha, to give back to the community that has helped me so much and to hopefully contribute, in some way...even if its by posing a question, to the growth of others.
Lastly, I began doing this in early 2015 and I plan on continuing to do so: I donate as much of the earnings that I get from SA on a monthly basis to various charities. Depending on how active I am writing each month, and what sort of side projects I have going on at the farm my wife and I recently purchased, the amount donated each month differs. However, I am pleased to be able to give back - I think its important to stay grounded and gracious when focusing so much on finances and these monthly donations help me not to lose sight of generosity.
*I should note that all articles that I write here are done so for my personal informational/educational purposes only. Any purchases that I make or opinions that I express are not meant as recommendations for anyone else. Please perform your own due diligence before following my lead into or out of a position. I am not a professional. I enjoy investing and the open discussion that articles on this site inspire - this is why I write, not to influence anyone else's decisions, but to enhance my own ability to make sound financial choices. That being said, I wish the best of luck to everyone. May we all meet our own financial goals.